Crinetics Pharmaceuticals Announces August 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals (Nasdaq: CRNX) has announced the granting of non-qualified stock options to fifteen new non-executive employees on August 10, 2024. The Compensation Committee approved options to purchase a total of 103,900 shares of common stock under the company's 2021 Employment Inducement Incentive Award Plan. These grants, made in accordance with Nasdaq Listing Rule 5635(c)(4), serve as inducements for new employees joining Crinetics.
The stock options have an exercise price of $47.64 per share, matching the closing price of Crinetics' stock on August 9, 2024. The vesting schedule spans four years, with 25% vesting after one year and the remainder vesting in 36 equal monthly installments, contingent on continued employment.
Crinetics Pharmaceuticals (Nasdaq: CRNX) ha annunciato il conferimento di opzioni su azioni non qualificate a quindici nuovi dipendenti non esecutivi il 10 agosto 2024. Il Comitato Compensi ha approvato opzioni per acquistare un totale di 103.900 azioni di azioni ordinarie secondo il Piano di Incentivazione all'Impiego del 2021 dell'azienda. Questi conferimenti, effettuati in conformità alla Regola di Quotazione Nasdaq 5635(c)(4), fungono da incentivo per i nuovi dipendenti che entrano a far parte di Crinetics.
Le opzioni su azioni hanno un prezzo di esercizio di $47,64 per azione, corrispondente al prezzo di chiusura delle azioni di Crinetics del 9 agosto 2024. Il programma di maturazione si estende su quattro anni, con il 25% che matura dopo un anno e il resto che matura in 36 rate mensili uguali, subordinatamente al mantenimento dell’impiego.
Crinetics Pharmaceuticals (Nasdaq: CRNX) ha anunciado la concesión de opciones sobre acciones no calificadas a quince nuevos empleados no ejecutivos el 10 de agosto de 2024. El Comité de Compensación aprobó opciones para comprar un total de 103,900 acciones de acciones comunes bajo el Plan de Incentivo por Empleo 2021 de la compañía. Estas concesiones, realizadas de acuerdo con la Regla de Cotización Nasdaq 5635(c)(4), sirven como incentivos para los nuevos empleados que se unen a Crinetics.
Las opciones sobre acciones tienen un precio de ejercicio de $47.64 por acción, que coincide con el precio de cierre de las acciones de Crinetics el 9 de agosto de 2024. El calendario de adquisición se extiende por cuatro años, con un 25% que se adquiere después de un año y el resto que se adquiere en 36 cuotas mensuales iguales, condicionado a la continuidad del empleo.
Crinetics Pharmaceuticals (Nasdaq: CRNX)는 2024년 8월 10일 15명의 새로운 비임원 직원에게 비자격 주식 옵션을 부여했다고 발표했습니다. 보상 위원회는 회사의 2021 고용 유도 인센티브 보상 계획에 따라 103,900주의 보통주를 구매할 수 있는 옵션을 승인했습니다. 이러한 부여는 Nasdaq 상장 규칙 5635(c)(4)에 따라 진행되며, Crinetics에 합류하는 새로운 직원들에 대한 유도 조건으로 작용합니다.
주식 옵션의 행사가격은 주당 $47.64로, 2024년 8월 9일 Crinetics 주식의 종가와 일치합니다. 취득 일정은 4년에 걸쳐 있으며, 1년 후 25%가 취득되고 나머지는 고용이 계속되는 조건으로 36개월에 걸쳐 동등한 월 분할로 취득됩니다.
Crinetics Pharmaceuticals (Nasdaq: CRNX) a annoncé l'octroi d'options sur actions non qualifiées à quinze nouveaux employés non exécutifs le 10 août 2024. Le Comité de Rémunération a approuvé des options pour acheter un total de 103 900 actions ordinaires dans le cadre du Plan d'Incitation à l'Emploi 2021 de l'entreprise. Ces attributions, réalisées conformément à la Règle de Cotation Nasdaq 5635(c)(4), servent d'incitations pour les nouveaux employés rejoignant Crinetics.
Les options d'achat d'actions ont un prix d'exercice de 47,64 $ par action, correspondant au prix de clôture des actions de Crinetics au 9 août 2024. Le calendrier d'acquisition s'étend sur quatre ans, avec 25 % d'acquisition après un an et le reste acquérant en 36 versements mensuels égaux, sous réserve de la continuité de l'emploi.
Crinetics Pharmaceuticals (Nasdaq: CRNX) hat die Gewährung von nicht qualifizierten Aktienoptionen an fünfzehn neue nicht-executive Mitarbeiter am 10. August 2024 bekannt gegeben. Der Vergütungsausschuss genehmigte Optionen zum Erwerb von insgesamt 103.900 Aktien des Unternehmens im Rahmen des 2021 Employment Inducement Incentive Award Plans. Diese Vergaben, die gemäß der Nasdaq-Listing-Regel 5635(c)(4) erfolgen, dienen als Anreiz für neue Mitarbeiter, die zu Crinetics stoßen.
Die Aktienoptionen haben einen Ausübungspreis von $47,64 pro Aktie, was dem Schlusskurs der Crinetics-Aktien am 9. August 2024 entspricht. Der Vesting-Zeitplan erstreckt sich über vier Jahre, wobei 25% nach einem Jahr und der Rest in 36 gleichen monatlichen Raten ausbezahlt wird, abhängig von der Fortführung des Arbeitsverhältnisses.
- Attraction of new talent with 15 non-executive employees joining the company
- Alignment of employee interests with shareholders through stock option grants
- Relatively high stock price of $47.64 per share, indicating positive market perception
- Potential dilution of existing shareholders' stake due to new stock option grants
SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on August 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 103,900 shares of its common stock to fifteen new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).
The 2021 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Crinetics, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with Crinetics, pursuant to Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Crinetics’ lead development candidate, paltusotine, is an investigational, first-in-class, oral, once-daily somatostatin receptor type 2 (SST2) agonist in Phase 3 clinical development for acromegaly and in Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics is also developing atumelnant (CRN04894), an investigational, first-in-class, oral ACTH antagonist, that is currently completing Phase 2 clinical studies for the treatment of congenital adrenal hyperplasia and Cushing’s disease. All of the company’s drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves’ disease (including thyroid eye disease), diabetes, obesity and GPCR-targeted oncology indications.
Investors:
Gayathri Diwakar
Head of Investor Relations
gdiwakar@crinetics.com
(858) 345-6340
Media:
Natalie Badillo
Head of Corporate Communications
nbadillo@crinetics.com
(858) 450-6464
FAQ
How many new employees received stock options from Crinetics Pharmaceuticals (CRNX) in August 2024?
What is the exercise price of the stock options granted by Crinetics Pharmaceuticals (CRNX) in August 2024?
How many shares of Crinetics Pharmaceuticals (CRNX) common stock can be purchased with the granted options?
What is the vesting schedule for the stock options granted by Crinetics Pharmaceuticals (CRNX) in August 2024?
